More Lung Cancer Patients Get Additional Immunotherapy Option
The FDA has expanded the use of an immune checkpoint inhibitor for the treatment of patients with lung cancer.
Progress Against Cancer
The FDA has expanded the use of an immune checkpoint inhibitor for the treatment of patients with lung cancer.
The FDA has approved a targeted therapy for certain patients with lung cancer.
The FDA has expanded the use of pembrolizumab to include patients with advanced lung cancer that has progressed and whose tumors test positive for the protein PD-L1.
A new combination of cancer immunotherapeutics has been approved by the FDA for treating certain patients with melanoma.
A new combination of drugs was approved by the U.S. FDA for treating certain patients with advanced colorectal cancer whose disease has worsened despite treatment with chemotherapy and a biological therapy.
Study presented at the AACR’s eighth annual cancer health disparities conference examines how improved diet reduced the risk of ovarian cancer in some African-American women. Despite the substantial progress made in preventing and treating...
Finding the latest discoveries in breast cancer care together. More than 7,000 breast cancer researchers, survivors, advocates, and others from 95 countries attended the 2015 San Antonio Breast Cancer Symposium (SABCS) in early December....
The former president, who announced in August 2015 he had metastatic melanoma, recently said he was cancer-free after treatment with pembrolizumab.
Two studies show that breast-conserving surgery plus radiation may be a better choice than mastectomy plus reconstruction for women with early-stage breast cancer because the first option reduces complications, improves long-term survival and costs...
Researchers find some physicians are missing opportunities to protect today's young people from future HPV-related cancers.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More